Vaxil Depreciation And Amortization vs Total Assets Analysis

VXL Stock  CAD 0.01  0.00  0.00%   
Vaxil Bio financial indicator trend analysis is much more than just breaking down Vaxil Bio prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Vaxil Bio is a good investment. Please check the relationship between Vaxil Bio Depreciation And Amortization and its Total Assets accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Depreciation And Amortization vs Total Assets

Depreciation And Amortization vs Total Assets Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Vaxil Bio Depreciation And Amortization account and Total Assets. At this time, the significance of the direction appears to have no relationship.
The correlation between Vaxil Bio's Depreciation And Amortization and Total Assets is 0.07. Overlapping area represents the amount of variation of Depreciation And Amortization that can explain the historical movement of Total Assets in the same time period over historical financial statements of Vaxil Bio, assuming nothing else is changed. The correlation between historical values of Vaxil Bio's Depreciation And Amortization and Total Assets is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Depreciation And Amortization of Vaxil Bio are associated (or correlated) with its Total Assets. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Total Assets has no effect on the direction of Depreciation And Amortization i.e., Vaxil Bio's Depreciation And Amortization and Total Assets go up and down completely randomly.

Correlation Coefficient

0.07
Relationship DirectionPositive 
Relationship StrengthInsignificant

Depreciation And Amortization

The systematic reduction in the recorded value of an intangible asset. This includes the allocation of the cost of tangible assets to periods in which the assets are used, representing the expense related to the wear and tear, deterioration, or obsolescence of physical assets and intangible assets over their useful lives.

Total Assets

Total assets refers to the total amount of Vaxil Bio assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Vaxil Bio books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.
Most indicators from Vaxil Bio's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Vaxil Bio current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vaxil Bio. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Selling General Administrative is likely to drop to 114.00 in 2024. Enterprise Value Over EBITDA is likely to climb to -9.3 in 2024
 2021 2022 2023 2024 (projected)
Total Operating Expenses986K584K254.0241.3
Cost Of Revenue25K2K1.8K1.7K

Vaxil Bio fundamental ratios Correlations

0.60.350.9-0.46-0.99-0.660.050.99-0.460.990.610.71-0.1-0.480.340.990.65-0.170.780.16-0.06-0.440.01-0.45-0.06
0.60.420.47-0.41-0.56-0.34-0.170.59-0.410.590.40.330.42-0.370.390.620.3-0.010.370.230.22-0.320.17-0.520.22
0.350.42-0.09-0.3-0.3-0.550.810.35-0.30.350.470.320.25-0.051.00.380.360.50.030.490.37-0.580.470.00.37
0.90.47-0.09-0.31-0.89-0.39-0.330.88-0.310.880.420.55-0.2-0.44-0.10.870.51-0.430.75-0.08-0.13-0.15-0.24-0.46-0.13
-0.46-0.41-0.3-0.310.560.73-0.08-0.541.0-0.54-0.45-0.7-0.150.45-0.28-0.56-0.66-0.16-0.65-0.70.350.87-0.450.830.35
-0.99-0.56-0.3-0.890.560.72-0.02-0.990.56-0.99-0.6-0.780.160.51-0.29-0.99-0.710.16-0.84-0.220.180.52-0.040.540.18
-0.66-0.34-0.55-0.390.730.72-0.39-0.70.73-0.7-0.63-0.940.120.58-0.55-0.71-0.86-0.24-0.79-0.530.380.84-0.330.520.38
0.05-0.170.81-0.33-0.08-0.02-0.390.06-0.080.060.320.150.040.180.830.070.210.43-0.170.360.26-0.430.320.30.26
0.990.590.350.88-0.54-0.99-0.70.06-0.541.00.60.75-0.15-0.460.351.00.71-0.120.80.23-0.07-0.510.06-0.5-0.07
-0.46-0.41-0.3-0.311.00.560.73-0.08-0.54-0.54-0.45-0.7-0.150.45-0.28-0.56-0.66-0.16-0.65-0.70.350.87-0.450.830.35
0.990.590.350.88-0.54-0.99-0.70.061.0-0.540.60.75-0.15-0.460.351.00.71-0.120.80.23-0.07-0.510.06-0.5-0.07
0.610.40.470.42-0.45-0.6-0.630.320.6-0.450.60.540.15-0.130.460.630.48-0.040.510.35-0.05-0.580.11-0.33-0.05
0.710.330.320.55-0.7-0.78-0.940.150.75-0.70.750.54-0.24-0.690.30.740.850.010.890.3-0.52-0.70.08-0.65-0.52
-0.10.420.25-0.2-0.150.160.120.04-0.15-0.15-0.150.15-0.24-0.20.23-0.06-0.24-0.01-0.190.20.2-0.060.16-0.180.2
-0.48-0.37-0.05-0.440.450.510.580.18-0.460.45-0.46-0.13-0.69-0.2-0.02-0.49-0.480.13-0.69-0.050.550.320.070.610.55
0.340.391.0-0.1-0.28-0.29-0.550.830.35-0.280.350.460.30.23-0.020.370.350.530.020.510.37-0.580.50.050.37
0.990.620.380.87-0.56-0.99-0.710.071.0-0.561.00.630.74-0.06-0.490.370.7-0.130.790.26-0.07-0.530.08-0.53-0.07
0.650.30.360.51-0.66-0.71-0.860.210.71-0.660.710.480.85-0.24-0.480.350.70.10.760.35-0.29-0.650.17-0.51-0.29
-0.17-0.010.5-0.43-0.160.16-0.240.43-0.12-0.16-0.12-0.040.01-0.010.130.53-0.130.1-0.170.590.1-0.410.860.180.1
0.780.370.030.75-0.65-0.84-0.79-0.170.8-0.650.80.510.89-0.19-0.690.020.790.76-0.170.27-0.61-0.570.05-0.67-0.61
0.160.230.49-0.08-0.7-0.22-0.530.360.23-0.70.230.350.30.2-0.050.510.260.350.590.27-0.07-0.870.88-0.28-0.07
-0.060.220.37-0.130.350.180.380.26-0.070.35-0.07-0.05-0.520.20.550.37-0.07-0.290.1-0.61-0.070.250.020.441.0
-0.44-0.32-0.58-0.150.870.520.84-0.43-0.510.87-0.51-0.58-0.7-0.060.32-0.58-0.53-0.65-0.41-0.57-0.870.25-0.650.540.25
0.010.170.47-0.24-0.45-0.04-0.330.320.06-0.450.060.110.080.160.070.50.080.170.860.050.880.02-0.65-0.060.02
-0.45-0.520.0-0.460.830.540.520.3-0.50.83-0.5-0.33-0.65-0.180.610.05-0.53-0.510.18-0.67-0.280.440.54-0.060.44
-0.060.220.37-0.130.350.180.380.26-0.070.35-0.07-0.05-0.520.20.550.37-0.07-0.290.1-0.61-0.071.00.250.020.44
Click cells to compare fundamentals

Vaxil Bio Account Relationship Matchups

Vaxil Bio fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets205K1.7M2.3M1.5M976K853.8K
Other Current Liab63K260K584.4K404.6K84.9K80.7K
Total Current Liabilities777K857K585K405K85K80.8K
Total Stockholder Equity(583K)804K1.7M1.1M891K446.7K
Property Plant And Equipment Net118K62K95K27K2K0.0
Net Debt(66K)(1.5M)(2.2M)(1.5M)(938K)(984.9K)
Retained Earnings(16.2M)(17.5M)(18.5M)(19.1M)(19.4M)(18.4M)
Accounts Payable618K588K559.0394.085.080.75
Cash753K83K1.5M2.2M938K665.5K
Non Current Assets Total118K62K95K27K2K0.0
Cash And Short Term Investments753K83K1.5M2.2M938K665.5K
Net Receivables11K33K35K20K19K21.4K
Common Stock Shares Outstanding88.9M101.7M136.1M137.0M137.0M143.8M
Liabilities And Stockholders Equity205K1.7M2.3M1.5M976K853.8K
Other Current Assets16K91K7K11K38.036.1
Other Stockholder Equity1.9M816K755K358K324K0.0
Total Liab788K857K585K405K85K80.8K
Total Current Assets110K1.6M2.3M1.5M976K723.9K
Accumulated Other Comprehensive Income3.6M3.7M3.8M3.8M4.2M2.3M
Net Tangible Assets435K(583K)804K1.7M2.0M2.1M
Short Term Debt29K5K6K9K8.1K8.8K
Property Plant Equipment62K95K27K2K1.8K1.7K
Net Invested Capital(583K)804K1.7M1.1M891K612.2K
Net Working Capital(667K)777K1.7M1.1M891K573.9K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Vaxil Stock Analysis

When running Vaxil Bio's price analysis, check to measure Vaxil Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vaxil Bio is operating at the current time. Most of Vaxil Bio's value examination focuses on studying past and present price action to predict the probability of Vaxil Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vaxil Bio's price. Additionally, you may evaluate how the addition of Vaxil Bio to your portfolios can decrease your overall portfolio volatility.